Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    Endocrine Society Responds to Insulin Glargine Studies With Recommendations - (DGNews)
    Everolimus Is an Effective Treatment Option for Patients With Pancreatic Neuroendocrine Tumours: Presented at ESMO-GI - (DGDispatch)
    Second Gene Linked to Familial Testicular Cancer - (DGNews)
    Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers - (N Engl J Med)
    Bariatric Surgery Could Lower Cancer Risk in Obese Women - (DGNews)

    News archive

     Recent webcasts/CME - Oncology Other

    Webcasts/CME archive

     Recent cases - Oncology Other
      Spontaneous Regression in Alveolar Soft Part Sarcoma: Case Report and Literature Review
      Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
      Synchronous Lingual and Thyroid Metastasis from Renal Cell Carcinoma
      Mucinous Cystic Neoplasms of the Mesentery: A Case Report and Review of the Literature
      Cardiovascular Magnetic Resonance Diagnosis of Cystic Tumor of the Atrioventricular Node

      Cases archive
        




      my personal edition > oncology other > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Drug Combination Has Activity In Inoperable Gastro-Oesophageal Cancers

      A DGReview of :"Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen."
      British Journal of Cancer

      10/17/2002
      By Elda Hauschildt


      The drug combination of irinotecan, mitomycin and cisplatin has activity in inoperable upper gastro-oesophageal cancers but also has a high toxicity profile, British researchers report.

      Investigators from St. Bartholomew's Hospital in London administered the combination therapy to 38 of 45 outpatients: 26 out of 31 patients with gastro-oesophageal cancer and 12 of 14 patients with pancreatic cancer, in a 28-day cycle.

      There was an overall response rate of 42 percent among both the gastro-oesophageal and the pancreatic cancer patients. Median survival was 9.5 months among the gastro-oesophageal patients and eight months among the pancreatic cancer patients.

      "There was a statistically significant increase in survival between those patients who achieved a stable disease response and those who achieved either a partial response or complete response," the researchers explain.

      Toxicity profiles for both types of cancer were virtually identical, they add.

      The total of treatment-related deaths was five. The admission rate was high, at 42 percent.

      Investigators suggest future developments could include reducing the dosage of irinotecan and the reducing the number of cycles to four.
      British Journal of Cancer, 2002; 87: 850-853. "Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen."

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send